gp120 binding
Recently Published Documents


TOTAL DOCUMENTS

84
(FIVE YEARS 1)

H-INDEX

36
(FIVE YEARS 0)

Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 1964
Author(s):  
Xinling Wang ◽  
Miao Cao ◽  
Yanling Wu ◽  
Wei Xu ◽  
Qian Wang ◽  
...  

Acquired immune deficiency syndrome (AIDS) has prevailed over the last 30 years. Although highly active antiretroviral therapy (HAART) has decreased mortality and efficiently controlled the progression of disease, no vaccine or curative drugs have been approved until now. A viral inactivator is expected to inactivate cell-free virions in the absence of target cells. Previously, we identified a gp120-binding protein, mD1.22, which can inactivate laboratory-adapted HIV-1. In this study, we have found that the gp41 N-terminal heptad repeat (NHR)-binding antibody D5 single-chain variable fragment (scFv) alone cannot inactivate HIV-1 at the high concentration tested. However, D5 scFv in the combination could enhance inactivation activity of mD1.22 against divergent HIV-1 strains, including HIV-1 laboratory-adapted strains, primary HIV-1 isolates, T20- and AZT-resistant strains, and LRA-reactivated virions. Combining mD1.22 and D5 scFv exhibited synergistic effect on inhibition of infection by divergent HIV-1 strains. These results suggest good potential to develop the strategy of combining a gp120-binding protein and a gp41-binding antibody for the treatment of HIV-1 infection.



2018 ◽  
Vol 34 (6) ◽  
pp. 2954-2962
Author(s):  
Vishnudatt Pandey ◽  
Gargi Tiwari ◽  
Rajendra Prasad Ojha

HIV-I cellular infection triggered by CD4 receptor protein and viral envelop glycoprotein gp120 binding event. CD4:gp120 surface is directed by the contact points of a hydrophobic gp120 cavity capped by Phe43CD4 and ionic bonds residues Arg59CD4 and Asp368gp120. The binding sites originated by gp120 and CD4 interaction leads to the entry of HIV-I into the host membrane, where, gp120 and a CD4 binding site becomes the main mark for plenty of drug uncovering program. Here, we took the crystal structure of small-molecule of gp120 in a complex that concurrently pursues both of the hotspots of gp120 binding sites. All ligands in our study are small molecules that are able to obstruct the protein-protein interactions between CD4 and gp120. This study aims at the thermodynamical insights of the ligand binding in CD4 binding sites using Molecular Dynamics Simulations Study and calculation of binding free energy. The physical of binding of drugs distinctly indicates a hydrophobic and electrostatics interaction motivated binding of ligands which explicitly mark CD4 binding sites.



2018 ◽  
Vol 14 (8) ◽  
pp. e1007278 ◽  
Author(s):  
Sakaorat Lertjuthaporn ◽  
Claudia Cicala ◽  
Donald Van Ryk ◽  
Matthew Liu ◽  
Jason Yolitz ◽  
...  


2018 ◽  
Vol 475 (5) ◽  
pp. 931-957 ◽  
Author(s):  
Bibek Parajuli ◽  
Kriti Acharya ◽  
Harry C. Bach ◽  
Bijay Parajuli ◽  
Shiyu Zhang ◽  
...  

We previously reported a first-generation recombinant DAVEI construct, a dual action virus entry inhibitor composed of cyanovirin-N (CVN) fused to a membrane proximal external region or its derivative peptide Trp3. DAVEI exhibits potent and irreversible inactivation of HIV-1 (human immunodeficiency virus) viruses by dual engagement of gp120 and gp41. However, the promiscuity of CVN to associate with multiple glycosylation sites in gp120 and its multivalency limit current understanding of the molecular arrangement of the DAVEI molecules on trimeric spike. Here, we constructed and investigated the virolytic function of second-generation DAVEI molecules using a simpler lectin, microvirin (MVN). MVN is a monovalent lectin with a single glycan-binding site in gp120, is structurally similar to CVN and exhibits no toxicity or mitogenicity, both of which are liabilities with CVN. We found that, like CVN-DAVEI-L2-3Trp (peptide sequence DKWASLWNW), MVN-DAVEI2-3Trp exploits a similar mechanism of action for inducing HIV-1 lytic inactivation, but by more selective gp120 glycan engagement. By sequence redesign, we significantly increased the potency of MVN-DAVEI2-3Trp protein. Unlike CVN-DAVEI2-3Trp, re-engineered MVN-DAVEI2-3Trp(Q81K/M83R) virolytic activity and its interaction with gp120 were both competed by 2G12 antibody. That the lectin domain in DAVEIs can utilize MVN without loss of virolytic function argues that restricted HIV-1 Env (envelope glycoprotein) glycan engagement is sufficient for virolysis. It also shows that DAVEI lectin multivalent binding with gp120 is not required for virolysis. MVN-DAVEI2-3Trp(Q81K/M83R) provides an improved tool to elucidate productive molecular arrangements of Env-DAVEI enabling virolysis and also opens the way to form DAVEI fusions made up of gp120-binding small molecules linked to Trp3 peptide.



2016 ◽  
Vol 48 (3) ◽  
pp. 275-281 ◽  
Author(s):  
Changzhong Jin ◽  
Jie Li ◽  
Linfang Cheng ◽  
Fumin Liu ◽  
Nanping Wu


PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0124839 ◽  
Author(s):  
Tahir Bashir ◽  
Mandar Patgaonkar ◽  
Selvaa Kumar C ◽  
Achhelal Pasi ◽  
Kudumula Venkata Rami Reddy
Keyword(s):  


2014 ◽  
Vol 194 (2) ◽  
pp. 637-649 ◽  
Author(s):  
Kathrin Zimmermann ◽  
Thomas Liechti ◽  
Anna Haas ◽  
Manuela Rehr ◽  
Alexandra Trkola ◽  
...  




2013 ◽  
Vol 125 (16) ◽  
pp. 4531-4535 ◽  
Author(s):  
Qiang Zhang ◽  
Jennifer Collins ◽  
Athina Anastasaki ◽  
Russell Wallis ◽  
Daniel A. Mitchell ◽  
...  
Keyword(s):  


2013 ◽  
Vol 52 (16) ◽  
pp. 4435-4439 ◽  
Author(s):  
Qiang Zhang ◽  
Jennifer Collins ◽  
Athina Anastasaki ◽  
Russell Wallis ◽  
Daniel A. Mitchell ◽  
...  
Keyword(s):  


Sign in / Sign up

Export Citation Format

Share Document